DHFR and breast carcinoma: In breast cancer, ADAR1 sustained cell viability and conferred methotrexate resistance in MCF-7 cells through miR-125a-3p/miR-25-3p-dependent A-to-I RNA editing of dihydrofolate reductase (DHFR) mRNA (Fig. 3e) [258].